Cyclopharm Ltd has released a press release.
CYC Institutional Placement - Premium To Share Price
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Cyclopharm
- Agreement to utilise cyclotron facility assets
- Pause in Trading
- CYC Business Update
- CYC Half Yearly Reports and Accounts
- Announcement of buy-back - Appendix 3C
Later from Cyclopharm
- Cyclopharm Company Update
- Cyclopharm Lodges NDA for Technegas with the USFDA
- USFDA Grants Cyclopharm USD$2.9m Application Fee Waiver
- Technegas Approved in Russia
- USFDA Approval to File Received for Technegas
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm